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HIV virological non‑suppression is highly
prevalent among 18‑ to 24‑year‑old youths
on antiretroviral therapy at the Kenyan coast
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Caroline Ngetsa1, Charles R. J. C. Newton1,3,4 and Amina Abubakar1,3,4,5

Abstract
Background: In sub-Saharan Africa, data on virologic outcomes of young people living with HIV (YLWH) enrolled on
antiretroviral therapy (ART) remains scarce. In this study, we describe the prevalence of HIV virological non-suppression (VNS) and its associated factors among YLWH aged 18–24 years from the Kenyan coast.
Methods: Data were analyzed for 384 YLWH who participated in a larger cross-sectional study conducted between
November 2018 and September 2019 in two counties at the Kenyan coast (Kilifi and Mombasa). Descriptive statistics
were used to summarize sample characteristics and logistic regression was used for statistical modeling of factors
associated with VNS. In this study, VNS was defined as plasma viral load ≥ 1000 copies/mL.
Results: Among these YLWH with a mean age of 20.7 years (SD = 2.2); 55.5% females, the overall prevalence of VNS
was 32.0% (95% Confidence interval (95% CI): 27.5, 36.9%). In the multivariable logistic regression analysis, being from a
largely rural setting (adjusted Odds Ratio (aOR) 1.73, 95% CI 1.10, 2.71; p = 0.02), underweight (aOR 1.87, 95% CI 1.16, 3.01;
p = 0.01) and low self-reported ART adherence (aOR 2.83, 95% CI 1.34, 6.00; p = 0.01) were significantly associated with
higher odds of VNS in YLWH.
Conclusions: In this study, high levels of VNS were observed among YLWH and this was significantly associated with
rural residency, nutritional and ART adherence problems. ART adherence counselling and nutritional support and
education should be intensified in this setting targeting YLWH residing mostly in rural areas. Given the high frequency
of VNS, there is need to closely monitor viral load and profile HIV drug resistance patterns in youths from the Kenyan
coast with confirmed virologic failure. The latter will help understand whether drug resistance also contributes to
poor viral suppression in addition to, or exclusive of suboptimal ART adherence.
Keywords: HIV infections, Antiretroviral therapy, Virological non-suppression, Prevalence, Young people, Youths living
with HIV, Risk indicators, Kenya
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Background
Globally, 3.4 million young people aged 15–24 years
were living with HIV by 2019 [1]—majority reside in subSaharan Africa (SSA) [2]. The number of young people
living with HIV (YLWH) continues to unprecedentedly
increase as more become newly HIV-infected, mostly
through sexual transmission [3]. Of the approximately
4500 new cases of HIV infection reported daily, about a
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third (31%) are among young people aged 15–24 years
[4] with a large proportion being youths from SSA [5].
In SSA, out of every four reported new HIV infections,
three occur in young people [6]. In Kenya, young people
aged 15–24 years contributed over half of new adult HIV
infections according to the 2015 estimates [7].
The advent, increasing access and continued adherence
to antiretroviral therapy (ART) has transformed the management of HIV from a fatal disease to now a manageable
chronic condition [8]. A key goal of ART is suppression
of viral replication leading to preservation of an optimal
state of health with improved immune functioning. In
terms of HIV treatment outcomes, consistent use of ART
has had substantial gains including declined HIV-related
morbidity and mortality [9] and improved survival [10].
A threat to these gains is the poor adherence to ART
observed among YLWH compared to younger children
and adults [11–13]. Not only does this poor adherence
place these youths at risk of HIV virological non-suppression (VNS) but also limits the efforts towards achieving the last two 95’s of the ambitious 95–95–95 HIV
treatment targets by the year 2030 [14]. According to the
World Health Organization (WHO) consolidated ART
guidelines for a public health approach [15], an individual
is considered to have VNS if their plasma viral (HIV-ribonucleic acid) load is ≥ 1000 copies/mL.
Studies from different geographical settings—mostly
in the West—have investigated virologic suppression status among YLWH on ART. In general, suboptimal level
of viral suppression among these youths is evident. In
a global review of virological outcomes of YLWH [16],
the prevalence of VNS ranged between 11 and 73%. In a
review of South African studies looking at YLWH’s viral
suppression among other aspects in the HIV continuum
of care, Zanoni et al. [17] report VNS prevalence ranging
from 7 to 27%. VNS can lead to adverse outcomes such as
higher risk of onward HIV transmission (for those who
engage in risky sexual behavior) [18], viral rebound [19],
faster disease progression and increased morbidity and
mortality [20]. Poor school attendance and lose of economic productivity have also been documented [21].
Investigations of the factors associated with VNS
among YLWH are generally scarce, more so in SSA. Most
of the existing studies are limited in terms of consensus
and some studies present contradictory findings, albeit
because of contextual differences. For instance, long
duration on ART was found to be significantly associated
with lower odds of VNS among Cambodian youths [22],
while among Ethiopian youths [23] this was associated
with significantly higher odds of VNS. In SSA, male sex
[24, 25] and poor ART adherence [24, 26] appear important risk indicators for VNS in YLWH; there is some consensus between studies but more research is warranted
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for a clear insight. Other risk indicators for VNS reported
by studies conducted in Ethiopia and Malawi include
WHO HIV clinical stage 2 [24], HIV-related stigma [25],
lower socioeconomic status and poor self-reported wellbeing [23]. Whether these are also important correlates
of VNS among YLWH across SSA is inconclusive; further
research evidence is needed from other SSA countries.
Data on virologic outcomes of YLWH enrolled on ART
in SSA is limited. In particular, knowledge about the factors associated with VNS in this sub-population is not
widely documented. In Kenya, we are aware of a recent
study investigating VNS among YLWH 10–24 years
old [27] but this study did not explore the factors independently associated with VNS and participants were
enrolled from an urban setting only. Information on correlates of VNS is critical in informing potential intervention areas for optimization of ART outcomes among
young people. In the present study, we: i) determined
the prevalence of VNS among YLWH 18–24 years old
enrolled from two diverse geographical settings at the
Kenyan coast; and ii) investigated the factors associated
with VNS among these young people.

Methods
Study design

This work is part of data collected from a larger crosssectional study conducted between November 2018 and
September 2019 along the Kenyan coast. The details of
the methodology have been described previously [28].
Below, we provide a brief description of the study setting,
participants and their recruitment process.
Study setting, participants and recruitment

Study participants were YLWH recruited through consecutive sampling from 20 geographically diverse HIVclinics in two counties at the Kenyan coast (Kilifi, n = 13
and Mombasa, n = 7). Kilifi County is largely a rural setting with an estimated population of 1.5 million people
[29]. HIV prevalence among individuals aged 15 years or
older in this County is estimated at 4.5%, slightly lower
than the national average prevalence of 6% [30]. Mombasa County is adjacent to Kilifi County. It is an urban
County hosting one of the three major cities of Kenya
(Mombasa) and has an estimated population of 1.2 million people [29]. HIV prevalence among individuals aged
15 years or older in this County is estimated at 7.5% [30].
Eligibility criteria in the larger study included: age range
of 18–24 years, a confirmed HIV-positive status, being
on ART and providing informed consent for participation. YLWH were identified from existing clinic records,
contacted, and invited for study briefs at a day coinciding
with the monthly teen support group meetings. Those
who could not be reached via available mobile contacts
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or without contact details were traced during their next
scheduled clinic appointment dates. Bookings for study
interviews were done after consenting participants had
been taken through the study in details by research assistants present at the time of the meeting. Eligible for the
present analysis were young people on ART for at least
6 months (see Fig. 1).
Sample size calculation

The sample size was originally calculated during the
design of the larger study based on key outcomes
described elsewhere [28]. In the present analysis, the
sample of 384 eligible participants is > 95% powered (at
5% level of significance) to detect a proportion of at least
0.20 given a null proportion of 0.11 [31]. The same sample is > 85% powered (at 5% level of significance) to carry
out a logistic regression analysis of correlates of VNS
based on previously reported effect sizes [23].
Measures
Outcome measure
Viral load quantification

Whole blood samples were collected from each of the
participating YLWH by the study nurse trained in phlebotomy. At the Clinical Trials Laboratory of the KEMRIWellcome Trust Research Programme, plasma samples
were extracted from each of the collected blood samples.
HIV viral load was quantified using the GeneXpert® Dx
System equipment (version 4.8; United States of America)
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utilizing about 1200 µL of plasma. All the remaining
plasma were individually labelled and archived at − 80 °C
for future investigations that will involve ART plasma
concentration and HIV drug resistance genotyping. In
the event the viral load test failed on the first attempt,
an extra 1200µL of archived plasma was retrieved for a
repeat run. In this study, YLWH were categorized as having VNS if their plasma viral load was ≥ 1000 copies/mL
in line with WHO recommendations [15]. All the viral
load results were also shared with the respective HIV
clinics to facilitate continuity of treatment.
Measures of exposure variables

Sociodemographic and asset index forms The sociodemographic form captured participant’s age, sex, educational level, employment status, religion, relationship status, area of residence, living status of parents and whom
they currently lived with. The asset index form gathered
information about individual or family ownership of disposable items as a proxy indicator of socioeconomic status.
Lifestyle and health history form This form captured
data on whether participants currently smoked cigarette,
chewed khat or used alcohol using a yes/no response
option via audio computer-assisted self-interview
(ACASI). Self-report information sought from YLWH
included disclosure of their HIV status, their level of satisfaction with current care and their view on accessibil-

Fig. 1 Recruitment flow chart for YLWH. ‡Due to a technical error on the electronic data capture platform, and participant could not be reached on
contact details provided for another interview. Pregnancy was one of the exclusion criteria applied in the larger study
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ity of their current point-of-care. YLWH were also asked
whether they experienced any current ART side effects or
an opportunistic infection, as informed by their clinician.
HIV‑related clinical data This included data on participant current ART regimen and duration they have been
on ART, WHO clinical staging of HIV, height and weight
(recorded during the most recent clinic visit) for body
mass index (BMI) computation, categorized as underweight (BMI < 18.5), normal (BMI of 18.5–24.9), overweight (BMI of 25.0–29.9) and obese (BMI ≥ 30.0). Participants were managed based on local guidelines on use
of antiretroviral drugs for treating and preventing HIV
infection [32].
Psychiatric symptoms A locally validated version of
the 9-item patient health questionnaire (PHQ-9) [33],
administered via ACASI, was used to assess presence of
depressive symptoms among the study participants. Items
on this measure are rated on a 4-point Likert scale of “0”
(not at all) to “3” (nearly every day). A total score ranging
between 0 and 27 is derived from the summation of item
scores. According to the scoring protocol [34], a cut-off
score of ≥ 10, also applicable for the Eastern Africa setting
[35], indicates positive screen for depressive symptoms.
The brief 12-item HIV stigma scale [36], administered
via ACASI, assessed participants’ perceived HIV-related
stigma. This scale is rated on a 4-point Likert scale as
“1” (strongly disagree), “2” (disagree) “3” (agree) and “4”
(strongly agree). Item scores are summated to derive
a total score ranging between 12 and 48, higher scores
indicative of a greater levels of perceived HIV-related
stigma.
The 4-item Morisky, Green and Levine Medication
Adherence Scale (MGLS) [37] was used as a self-report
measure of ART adherence. This measure was also
administered via ACASI. The MGLS has a total score
ranging between 0 and 4. Based on this score, there
are 3 levels of medication adherence: high (a score
of 0), medium (scores of 1 or 2), and low adherence
(scores ≥ 3).
Statistical analysis

All analyses were conducted in STATA version 15.0
(StataCorp LP, College Station, Texas, United States
of America). Basic descriptive statistics (means [SD],
frequencies and percentages) were used to summarize sample characteristics by group viral suppression
status (virally suppressed vs. non-suppressed groups).
Chi-squared (χ2) test and independent Student’s t-test
were used to compare group differences for categorical and continuous variables, respectively. Proportions
as percentages were used to estimate the prevalence of
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VNS. Univariate logistic regression analysis was used to
assess the crude association between exposure variables
(sociodemographic, psychosocial and HIV-related factors) and the outcome variable (VNS). All variables with
p < 0.25 from univariate analyses were taken forward to
the multivariable logistic regression analysis which was
used to investigate factors independently associated
with VNS. Backward stepwise logistic regression models were fit in the multivariable model building process,
removing all variables with p > 0.05 (one at a time). Collinearity diagnostics were performed for the final multivariable model, with no multicollinearity problems
identified based on interpretation of the variance inflation factor. A p-value > 0.05 in the Hosmer–Lemeshow
goodness of fit test was considered a well-fitting final
logistic regression model. For all tests of hypothesis, a
two-tailed p-value of < 0.05 was considered statistically
significant, with a confidence interval of 95% used to
report on the precision of the reported estimates.

Results
Participant characteristics

Table 1 shows the participant sociodemographic, psychosocial and HIV-related characteristics presented by
HIV viral load suppression status, alongside results from
univariate logistic regression analyses. In summary, the
mean age of the participants was 20.7 years (SD = 2.2),
more than half (55.5%) were females. Over a quarter of
the participants screened positive for depressive symptoms (27.9%). Most of the participants had a BMI within
the normal range (59.9%), were on ART for over 5 years
(61.2%), largely first line regimen (80.5%), and were highly
adherent based on self-report (65.9%). Participants’ mean
asset index and perceived HIV-related stigma scores were
2.2 (SD = 1.6) and 25.9 (SD = 7.4), respectively.
Prevalence of VNS among YLWH on ART from the Kenyan
coast

Figure 2 depicts the HIV viral load suppression status
among young people on ART from the Kenyan coast.
Most of these young people (56%) had undetectable HIV
viral load (< 40copies/mL). The overall prevalence of VNS
was high, 32.0% (95% Confidence interval (95% CI): 27.5,
36.9%). The prevalence of VNS was significantly higher
among YLWH from the rural setting compared to those
from the urban setting, 37.8% (95% CI 30.8, 44.7%) vs
26.5% (95% CI 20.3, 32.7%); p = 0.02.
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Table 1 Participant characteristics by HIV viral load suppression status and associated crude odds ratio
Viral suppression status

Unadjusted OR

Sociodemographic factors
Area of residence

Urban

196 (51.0)

144 (55.2)

52 (42.3)

Ref

Rural

188 (49.0)

117 (44.8)

71 (57.7)

1.68 (1.09, 2.60)

0.02

Age (years)

Mean (SD)

20.7 (2.2)

20.7 (2.2)

0.99 (0.89, 1.09)

0.80

Sex

Female

213 (55.5)

150 (57.5)

63 (51.2)

Ref

Male

171 (44.5)

111 (42.5)

60 (48.8)

1.29 (0.84, 1.98)

None

7 (1.8)

6 (2.3)

1 (0.8)

Primary

151 (39.3)

106 (40.6)

45 (36.6)

2.55 (0.30, 21.77)

0.39

Secondary

168 (43.8)

107 (41.0)

61 (49.6)

3.42 (0.40, 29.08)

0.26

Tertiary

58 (15.1)

42 (16.1)

16 (13.0)

2.29 (0.25, 20.50)

0.46

Employed

53 (13.8)

37 (14.2)

16 (13.0)

Ref

Education level

Employment

Religion

Relationship status
Living arrangement

0.25

Ref

Student

138 (35.9)

95 (36.4)

43 (35.0)

1.05 (0.53, 2.08)

0.90

Unemployed

193 (50.3)

129 (49.4)

64 (52.0)

1.15 (0.59, 2.22)

0.68

12 (3.1)

9 (3.5)

3 (2.4)

Christian

287 (74.7)

195 (74.7)

92 (74.8)

1.42 (0.37, 5.35)

0.61

Muslim

85 (22.1)

57 (21.8)

28 (22.8)

1.47 (0.37, 5.87)

0.58

With a p
 artner1

64 (16.7)

49 (18.8)

15 (12.2)

Ref

No partner2

320 (83.3)

212 (81.2)

108 (87.8)

Living alone

34 (8.9)

27 (10.3)

7 (5.7)

343 (89.3)

230 (88.1)

113 (91.9)

1.90 (0.80, 4.48)

7 (1.8)

4 (1.5)

3 (2.4)

2.89 (0.52, 16.03)

0.22

2.2 (1.6)

2.2 (1.6)

2.3 (1.7)

1.06 (0.93, 1.21)

0.38

Ref

No religion

Family/relative
Friend/other
Asset index scorea

20.7 (2.2)

Mean (SD)

Ref

1.66 (0.89, 3.10)

0.11

Ref
0.15

HIV-related factors
Body Mass Index

Normal

230 (59.9)

164 (62.8)

66 (53.7)

Overweight

26 (6.8)

19 (7.3)

7 (5.7)

0.92 (0.37, 2.28)

0.85

Obese

13 (3.4)

12 (4.6)

1 (0.8)

0.21 (0.03, 1.62)

0.13

1.84 (1.16, 2.94)

0.01

Underweight

115 (30.0)

66 (25.3)

49 (39.8)

WHO HIV clinical stage (missing = 1)

Stage 1 & Stage 2

330 (86.2)

225 (86.5)

105 (85.4)

Current ART regimen

First line

53 (13.8)

35 (13.5)

18 (14.6)

1.10 (0.60, 2.04)

309 (80.5)

212 (81.2)

97 (78.9)

Ref

Second line

75 (19.5)

49 (18.8)

26 (21.1)

1.16 (0.68, 1.98)

< 1 year

25 (6.5)

21 (8.0)

4 (3.3)

1–5 years

124 (32.3)

90 (34.5)

34 (27.6)

1.98 (0.63, 6.20)

0.24

> 5 years

235 (61.2)

150 (57.5)

85 (69.1)

2.97 (0.99, 8.95)

0.05

Any ART side effects (missing = 1)

No

279 (72.9)

187 (71.9)

92 (74.8)

Ref

Yes

104 (27.1)

73 (28.1)

31 (25.2)

0.86 (0.53, 1.41)

ART Adherence

High adherence

238(62.0)

172 (65.9)

66 (53.7)

Ref

Medium

Duration on ART

Any current opportunistic infection

Stage 3 & Stage 4

Ref
0.76
0.59

Ref

0.56

111 (28.9)

71 (27.2)

40 (32.5)

1.47 (0.91, 2.37)

0.12

Low

35 (9.1)

18 (6.9)

17 (13.8)

2.46 (1.20, 5.06)

0.01

No

360 (93.7)

251 (96.2)

109 (88.6)

Yes

24 (6.3)

10 (3.8)

14 (11.4)

3.22 (1.39, 7.48)

All alive

115 (30.0)

84 (32.2)

31 (25.2)

Ref

One parent alive

141 (36.7)

87 (33.3)

54 (43.9)

1.68 (0.99, 2.87)

0.06

Both Died

128 (33.3)

90 (34.5)

38 (30.9)

1.14 (0.65, 2.00)

0.64

19 (5.0)

18 (6.9)

1 (0.8)

Yes, family only

312 (81.2)

208 (79.7)

104 (84.6)

9.00 (1.19, 68.35)

0.03

Yes, very open

53 (13.8)

35 (13.4)

18 (14.6)

9.26 (1.14, 75.02)

0.04

Ref
0.01

Psychosocial factors
Parental loss

Disclosure of HIV status

No

Ref
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Table 1 (continued)
Viral suppression status
Clinic accessibility

< 30 min travel time

123 (32.0)

86 (33.0)

37 (30.1)

Ref

30 min–1 h

166 (43.2)

112 (42.9)

54 (43.9)

1.12 (0.68, 1.85)

0.66

95 (24.7)

63 (24.1)

32 (26.0)

1.18 (0.66, 2.10)

0.57

364 (94.8)

246 (94.3)

118 (95.9)

> hour travel time
Satisfaction with current care

Satisfied
Unsatisfied

Currently smoking
Current use of khat
Current alcohol use
Depressive symptoms
Perceived HIV stigma

Unadjusted OR

No

20 (5.2)

15 (5.7)

5 (4.1)

367 (95.6)

250 (95.8)

117 (95.1)

Yes

17 (4.4)

11 (4.2)

6 (4.9)

No

355 (92.4)

245 (93.9)

110 (89.4)

Yes

29 (7.6)

16 (6.1)

13 (10.6)

No

334 (87.0)

232 (88.9)

102 (82.9)

Ref
0.69 (0.25, 1.96)

0.49

Ref
1.17 (0.42, 3.23)

0.77

Ref
1.81 (0.84, 3.89)

0.13

Ref

Yes

50 (13.0)

29 (11.1)

21 (17.1)

1.65 (0.90, 3.03)

No

277 (72.1)

196 (75.1)

81 (65.8)

Ref

42 (34.2)

1.56 (0.98, 2.49)

0.06

1.02 (0.99, 1.05)

0.17

yes

107 (27.9)

Mean (SD)

25.9 (7.4)

65 (24.9)
25.6 (7.6)

26.7 (6.9)

0.11

All values are presented as frequency (percent) unless otherwise stated
1

Included those who were married or cohabiting

2

Included those who were never married, those widowed, divorced or separated

a

Score range = 0 to 7, higher scores indicate better socioeconomic status

SD standard deviation, CI confidence interval, OR odds ratio, HIV human immunodeficiency virus, ARTantiretroviral therapy, WHO World Health Organization

Fig. 2 HIV viral load suppression status among young people, 18–24 years old, on ART from coastal Kenya, n = 384

Factors associated with VNS among young people
from coastal Kenya

The univariate logistic regression analysis showed
that being from a rural setting, underweight, low
self-reported ART adherence, presence of a current
opportunistic infection and disclosure of HIV status
significantly increased the odds of VNS (Table 1). Lack
of a partner, living with others, being obese, being on
ART for a year or more, medium ART adherence, loss
of one parent, current khat use, presence of depressive
symptoms and higher perceived HIV-related stigma
were associated with VNS at p < 0.25 (Table 1) and were

all included in the multivariable logistic regression
analysis.
Under the final multivariable logistic regression analysis, being from a rural setting (aOR 1.73 95% CI 1.10,
2.71; p = 0.02), underweight (aOR 1.87 95% CI 1.16, 3.01;
p = 0.01) and low self-reported adherence to ART (aOR
2.83 95% CI 1.34, 6.00; p = 0.01) were significantly associated with higher odds of VNS. Hosmer–Lemeshow
goodness of fit statistic for the final regression model was
X2(15) = 9.97; p = 0.82.
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Discussion
In this cross-sectional study from the Kenyan coast,
we describe the prevalence and factors associated with
VNS among YLWH aged 18–24 years. Almost a third
(32%) of these youths were virally non-suppressed and
this was significantly associated with rural residence,
being underweight and low ART adherence. Other
studies investigating VNS among YLWH in SSA and
beyond report varying prevalence estimates, some similar to what we observed, for instance estimates of 26%
reported by a study conducted in Ethiopia [24], 37% in
South Africa [19], 39% in Malawi [25], 40% in Tanzania
[38], and 23% in Cambodia [22]. We found VNS prevalence of 27% among participants from the urban setting
which compares to the VNS prevalence of 26% reported
by Kangethe et al. [27] in their study involving YLWH
recruited from a tertiary facility in Kenya’s capital city of
Nairobi.
Across the above studies documenting VNS prevalence, of note is the differences in the threshold applied
when defining VNS and the recruited age groups of
YLWH which may account for the variation in prevalence estimates. For instance, the South African [19] and
Tanzanian [38] studies may have recorded estimates on
the higher side because of using a much lower threshold to define VNS i.e. plasma viral load ≥ 400 copies/mL.
The rest of the studies applied a threshold similar to our
study i.e. plasma viral load ≥ 1000 copies/mL. However,
the Malawian study [25] recruited a broader age group of
13 to 24-year-old YLWH whereas the Cambodian study
[22] recruited a narrower age group of 15 to 17-year-old
YLWH. This, in addition to contextual differences may
explain the extreme ends of observed VNS prevalence
in these two studies (39% vs. 23%). At the Kenyan coast,
the observed prevalence of VNS among YLWH aged
18–24 years is higher than the 25% prevalence estimate
reported by Hassan et al. [39] among the general adult
population living with HIV. These authors used a threshold of plasma viral load ≥ 400 copies/mL to define VNS.
Arguably, their observed prevalence estimate would have
been lower if a much higher threshold were applied.
As would be expected and consistent with previous
findings [24, 26, 39, 40], the odds of VNS were significantly higher among participants who self-reported low
ART adherence. Since excellent ART adherence mediates the relationship between ART use and virologic
suppression [41, 42], there is need for intensification of
ART adherence support among YLWH facing adherence challenges to avoid viral rebound, virologic failures
or the development of HIV drug resistance, especially if
routine viral load monitoring is not readily available. The
adherence approach should follow the caring, respectful and compassionate model of care [43]. This approach
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is particularly important for YLWH since they are more
likely to be lost from care [12] for instance if it appears
they are being censured for missed ART doses during
the adherence support sessions. Additionally, barriers to
optimal ART adherence among YLWH should be identified and addressed at an individual level. Some of the
commonly reported barriers among YLWH include suboptimal disclosure of HIV status [44, 45], forgetfulness
or being busy with different activities [46], anticipated
HIV-related stigma [44, 46], psychological distress [46,
47], substance use [46, 48], inadequate social support and
lower medication self-efficacy [49]. Beyond VNS, suboptimal ART adherence may eventually result in ART
resistance problems and this can compromise available
and future ART options [50].
To the best of our knowledge, this is the first study
from SSA to report a significant association between low
BMI (being underweight relative to normal body weight)
and higher odds of VNS among YLWH. Similar associations have been reported in studies involving the general
adult population with HIV [51–53]. Contrast to our finding, a study conducted in Northeast Ethiopia [40] found a
null association. At the Kenyan coast, where the levels of
inequality and poverty are high [54], the undernutrition
observed among YLWH (30% were underweight) could
be a proxy marker for inadequate access to foods rich in
nutrients due to lack of resources. ART medications are
strong and individuals on ART are often required to take
highly nutritious food (e.g., up to five servings a day is
recommended in our setting) but in the absence of means
to afford such nutritious food, instances of YLWH taking
ART on an empty stomach, missing some doses or not
taking it at all (hence poor adherence) have been reported
[55, 56]. As such, poor viral suppression is expected.
However, in the inverse direction, it is plausible that persistent VNS can lead to body wasting hence lower BMI.
Therefore, the direction of the association between BMI
and VNS can only be discerned by studies of longitudinal design. Nonetheless, to overcome any poverty-related
ART adherence obstacle in our setting, nutritional support programmes facilitated by the government or other
donors and run through the HIV clinics are recommended. Nutritional counselling should be promoted at
the HIV clinics, educating YLWH about food types with
the most benefit to their body while on ART but at the
same time considering the cost implications.
In this study, rural residency was significantly associated with nearly twofold higher odds of VNS. This
finding is difficult to compare within the literature of
virologic outcomes in YLWH; we are not aware of any
study that reports this kind of association. However, the
finding is supported by an investigation from Ethiopia
involving adults living with HIV [57]. Living in a rural
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area could be an indirect marker of treatment interruption because of reasons such as difficulties in accessing HIV treatment services. In remote areas of Kenya,
healthcare services are often inaccessible as health facilities are a distant away and roads leading into such facilities are often in bad condition, attracting high transport
costs [58]. The high transport costs may be a deterrent
to YLWH in seeking routine HIV care, especially if the
financial obligation lies with them. Treatment interruption is significantly associated with poor virological and
immunological outcomes [57].
We did not observe any significant associations
between VNS and demographic variables of age and sex.
In contrast, other studies have found significant association between VNS and youth age [22–24] or sex [24, 59].
In support of our finding, an Ethiopian study [23] found
a null association between VNS and participant sex. We
think that the lack of association in our study may be
because these young people aged 18 to 24 years are at a
developmental age where they are equally exposed to the
challenges of transitioning into adulthood while living
with HIV, regardless of gender. For instance, as they are
now considered adults by law and society, it is expected
that they take charge of aspects of individual health
including ART taking (without close monitoring anymore) and honoring clinic appointments for ART refill or
regular check-up.
HIV-related stigma has been associated with higher
odds of VNS in YLWH [25] but this association was not
replicated in our study. Furthermore, no associations
were observed between VNS and any of the HIV clinical factors including ART regimen, duration on ART and
WHO clinical staging (at either the univariate or multivariable analyses). Presence of opportunistic infection
was significantly associated with VNS at the univariate
but not multivariable analyses. These findings generally
contrast findings from studies involving YLWH [22–24]
but compares to those from previous reports involving
general adults living with HIV [40, 52]. The range and
level of care that these YLWH receive at the HIV clinics may be a mitigating factor, over 90% of them selfreported being satisfied with the care they received at
their point of care.
The findings reported in this study should be interpreted in the context of several study limitations. First,
the cross-sectional analyses do not allow for any causal
inference. Second, we did not include underlying HIV
drug resistance in the analyses, and this could also be a
cause of VNS [60]. Future analysis of data from this subpopulation will help arbitrate the contribution of HIV
drug resistance to VNS in coastal Kenya, aside from suboptimal ART adherence. This line of enquiry will be particularly important in the minimization of unnecessary/
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premature ART regimen switch—often to limited and
expensive options [60]. Third, data on ART adherence
was based on self-report, which may be affected by recall
and social desirability bias. Fourth, study findings may
not be generalizable to YLWH outside the study context.
Relatedly, even within the study context, caution should
be exercised in generalizing findings to all YLWH since
we only recruited participants from public HIV facilities
and used consecutive sampling method. Some YLWH
could be accessing services exclusively from private facilities offering HIV-related services.

Conclusion
A considerable proportion of YLWH in this study were
virally non-suppressed. In this setting, rural residency,
being underweight and poor ART adherence are important indicators associated with VNS that necessitate
intensified adherence counselling and nutritional support
and education which should target YLWH mostly from
rural areas. Given the high frequency of VNS, there is
need to closely monitor viral load and profile HIV drug
resistance patterns in youths from the Kenyan coast with
confirmed virologic failure. The latter will help understand whether drug resistance also contributes to poor
viral suppression in addition to, or exclusive of suboptimal ART adherence but also inform the need for ART
regimen switching.
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